Denali Therapeutics logo

Denali Therapeutics share price today

(DNLI)

Denali Therapeutics share price is $20.78 & ₹1,768.27 as on 24 Dec 2024, 2.30 'hrs' IST

$20.78

-0.67

(-3.12%)

Market is closed - opens 8 PM, 24 Dec 2024

View live Denali Therapeutics share price in Dollar and Rupees. Guide to invest in Denali Therapeutics from India. Also see the sentimental analysis on Indian investors investing in Denali Therapeutics. Get details on the Indian mutual funds that are investing in Denali Therapeutics. Get Analyst recommendations and forecasts along with all the Denali Therapeutics's financials.

Denali Therapeutics share price movements

  • Today's Low: $20.61
    Today's High: $21.37

    Day's Volatility :3.56%

  • 52 Weeks Low: $14.56
    52 Weeks High: $33.33

    52 Weeks Volatility :56.32%

Denali Therapeutics Returns

PeriodDenali Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-31.46%
-10.0%
0.0%
6 Months
-7.19%
-5.7%
0.0%
1 Year
-7.02%
2.8%
0.0%
3 Years
-53.71%
-0.4%
-21.1%

Denali Therapeutics Key Statistics

in dollars & INR

Previous Close
$21.45
Open
$21.24
Today's High
$21.37
Today's Low
$20.61
Market Capitalization
$3.0B
Today's Volume
$922.7K
52 Week High
$33.33
52 Week Low
$14.56
Revenue TTM
$0.0
EBITDA
$-511.9M
Earnings Per Share (EPS)
$-2.76
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-35.09%

How to invest in Denali Therapeutics from India?

It is very easy for Indian residents to invest directly in Denali Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Denali Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Denali Therapeutics or DNLI on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Denali Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Denali Therapeutics shares which would translate to 0.041 fractional shares of Denali Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Denali Therapeutics, in just a few clicks!

Returns in Denali Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Denali Therapeutics investment value today

Current value as on today

₹95,297

Returns

₹4,703

(-4.7%)

Returns from Denali Therapeutics Stock

₹7,025 (-7.02%)

Dollar Returns

₹2,322 (+2.32%)

Indian investors sentiment towards Denali Therapeutics

33%

Period: Sep 24, 2024 to Dec 23, 2024. Change in 30 Days versus previous period

Search volume for Denali Therapeutics on INDmoney from India has grown in the last 30 days as on Dec 24, 2024. 33% more investors are searching Denali Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Denali Therapeutics

  • Baillie Gifford & Co Limited.

    9.27%

  • BlackRock Inc

    9.15%

  • Vanguard Group Inc

    7.77%

  • Wellington Management Company LLP

    7.45%

  • Capital Research Global Investors

    5.50%

  • FMR Inc

    5.44%

Analyst Recommendation on Denali Therapeutics

Buy

    86%Buy

    13%Hold

    0%Sell

Based on 23 Wall street analysts offering stock ratings for Denali Therapeutics(by analysts ranked 0 to 5 stars)

Based on 23 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
20
20
20
Hold
3
3
3
Sell
0
0
0

Analyst Forecast on Denali Therapeutics

What analysts predicted

Upside of 105.82%

Current:

$20.78

Target:

$42.77

Insights on Denali Therapeutics

  • Price Movement

    In the last 7 days, DNLI stock has moved down by -10.5%
  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 294.12M → -305.04M (in $), with an average decrease of 12137.8% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -99.02M → -107.19M (in $), with an average decrease of 8.3% per quarter
  • DNLI vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 26.8% return, outperforming this stock by 32.2%
  • DNLI vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 24.7% return, outperforming this stock by 80.9%

Denali Therapeutics Technicals Summary

Sell

Neutral

Buy

Denali Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Denali Therapeutics Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Denali Therapeutics Inc
-15.18%
-7.19%
-7.02%
-53.71%
9.14%
Regeneron Pharmaceuticals, Inc.
-4.59%
-33.24%
-15.82%
12.66%
90.77%
Biontech Se
-6.0%
34.52%
8.38%
-55.46%
241.9%
Alnylam Pharmaceuticals, Inc.
-3.47%
0.88%
26.71%
50.37%
105.71%
Vertex Pharmaceuticals Incorporated
-12.22%
-14.47%
-0.59%
82.27%
84.0%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Denali Therapeutics Inc
NA
NA
NA
-2.83
-0.35
-0.24
NA
9.17
Regeneron Pharmaceuticals, Inc.
17.36
17.36
1.04
45.07
0.17
0.07
NA
272.04
Biontech Se
160.8
NA
0.04
-3.11
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.19
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
32.84
NA
1.04
0.54
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Denali Therapeutics Inc
Buy
$3.0B
9.14%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Buy
$77.1B
90.77%
17.36
33.61%
Biontech Se
Buy
$27.1B
241.9%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Buy
$31.7B
105.71%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Buy
$102.3B
84.0%
32.84
-4.51%

Denali Therapeutics Dividend announcements

  • Denali Therapeutics Earnings

    Denali Therapeutics’s price-to-earnings ratio stands at None

    Read More

About Denali Therapeutics

denali therapeutics inc. (“denali”) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including alzheimer’s disease, parkinson’s disease, als and others. denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. founding investors include fidelity biosciences, arch venture partners, flagship ventures and the alaska permanent fund (represented by crestline investors).
Organization
Denali Therapeutics
Employees
390
CEO
Dr. Ryan J. Watts Ph.D.
Industry
Health Technology

Management People of Denali Therapeutics

NameTitle
Dr. Ryan J. Watts Ph.D.
Co-Founder, President, CEO & Director
Dr. Alexander O. Schuth M.D.
Co-Founder, CFO, COO & Secretary
Dr. Marc Tessier-Lavigne Ph.D.
Co-Founder & Independent Director
Dr. Carole Ho M.D.
Chief Medical Officer & Head of Development
Mr. Tyler M. Nielsen
Senior Vice President of Corporate Finance
Dr. Dana Andersen
Chief Technical and Manufacturing Officer
Mr. Joe Lewcock Ph.D.
Chief Scientific Officer
Dr. Laura Hansen
Vice President of Investor Relations
Mr. Chris Walsh J.D.
General Counsel
Mr. Mark Rowen
Vice President of Corporate Development

Important FAQs about investing in Denali Therapeutics from India :

What is Denali Therapeutics share price today?

Denali Therapeutics share price today stands at $20.78, Open: $21.24 ; Previous Close: $21.45 ; High: $21.37 ; Low: $20.61 ; 52 Week High: $33.33 ; 52 Week Low: $14.56. The stock opens at $21.24, after a previous close of $21.45. The stock reached a daily high of $21.37 and a low of $20.61, with a 52-week high of $33.33 and a 52-week low of $14.56.

Can Indians buy Denali Therapeutics shares?

Yes, Indians can invest in the Denali Therapeutics (DNLI) from India.

With INDmoney, you can buy Denali Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Denali Therapeutics at zero transaction cost.

How can I buy Denali Therapeutics shares from India?

It is very easy to buy Denali Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Denali Therapeutics be purchased?

Yes, you can buy fractional shares of Denali Therapeutics with INDmoney app.

What are the documents required to start investing in Denali Therapeutics stocks?

To start investing in Denali Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Denali Therapeutics

Today’s highest price of Denali Therapeutics (DNLI) is $21.37.

Today’s lowest price of Denali Therapeutics (DNLI) is $20.61.

What is today's market capitalisation of Denali Therapeutics

Today's market capitalisation of Denali Therapeutics DNLI is 3.0B

What is the 52 Week High and Low Range of Denali Therapeutics

  • 52 Week High

    $33.33

  • 52 Week Low

    $14.56

What are the historical returns of Denali Therapeutics?

  • 1 Month Returns

    -15.18%

  • 3 Months Returns

    -7.19%

  • 1 Year Returns

    -7.02%

  • 5 Years Returns

    9.14%

Who is the Chief Executive Officer (CEO) of Denali Therapeutics

Dr. Ryan J. Watts Ph.D. is the current Chief Executive Officer (CEO) of Denali Therapeutics.